People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Media & Content, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bitmovin, Inc. | — | Media & Content | Series B | $77.0M | $15.5M | 2021 |
| Palisade Bio, Inc. | — | Biotechnology | Series B | $57.3M | $30.4M | 2020 |
| NexImmune, Inc. | — | Biotechnology | Series B | $35.0M | $308.3M | 2011 |
| Beta Cat Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $5.5M | $98.9M | 2016 |
| Neodiagnostix Inc | — | Biotechnology | Seed | $1.5M | $67.0M | 2009 |
| Noble Life Sciences, Inc. | — | Biotechnology | Pre-Seed | $235K | $13.0M | 2010 |
Kenneth Carter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kenneth Carter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alain Cappeluti | 2 | 2 |
| Teddie Wardi | 1 | 10 |
| Robert Spiegel | 1 | 8 |
| James Eadie | 1 | 6 |
| Ben Blume | 1 | 6 |
| James Barrett | 1 | 6 |
| Joe Cunningham | 1 | 5 |
| Joseph Cunningham | 1 | 4 |
| Kenneth C Carter | 1 | 4 |
| Donald Williams | 1 | 4 |
| Scott Ogilvie | 1 | 4 |
| Tony Yao | 1 | 3 |
| Janis Naeve | 1 | 3 |
| Rahul Aras | 1 | 3 |
| Richard Daly | 1 | 3 |
| Catherine Sohn | 1 | 3 |
| David Mazzo | 1 | 3 |
| I. Richard Garr | 1 | 2 |
| Cristina Csimma | 1 | 2 |
| Sunil P. Sharma | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.